How India Exports Naproxen to the World

In the United States, naproxen is approved through multiple Abbreviated New Drug Applications (ANDAs). Notably, ANDA 74-936 for naproxen delayed-release tablets was approved on February 24, 1998, for Purepac Pharmaceutical Co. Subsequently, ANDA 75-390 received approval on April 19, 2001, for King and Spalding. Additionally, ANDA 207457 for sumatriptan and naproxen tablets (85 mg/500 mg) was approved for Aurobindo Pharma USA, Inc.

The regulatory pathway for naproxen in the U.S. involves demonstrating bioequivalence to the reference listed drug (RLD) through the ANDA process. Given the substantial number of Indian exporters (192) supplying naproxen to the U.S., compliance with FDA regulations, including Good Manufacturing Practices (GMP) and bioequivalence standards, is imperative to maintain market access.

In the European Union, naproxen is subject to marketing authorization requirements overseen by the European Medicines Agency (EMA). The EMA conducts periodic safety update report single assessments (PSUSAs) for naproxen to ensure ongoing pharmacovigilance. For instance, procedure PSUSA/00002125/202308 resulted in a variation to the marketing authorization in June 2024. (ema.europa.eu)

Manufacturers exporting to the EU and UK must adhere to EU Good Manufacturing Practice (GMP) guidelines, which encompass quality management, personnel, premises, equipment, documentation, production, quality control, and self-inspection. Compliance with these standards is essential for obtaining and maintaining marketing authorizations within these jurisdictions.

Naproxen is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in global healthcare. The drug is also subject to international pharmacopoeial standards, including those of the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP). Adherence to these standards ensures the quality, safety, and efficacy of naproxen products in the global market.

In India, naproxen is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, specific ceiling prices for naproxen are subject to periodic revisions. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceutical products, ensuring compliance with national regulations.

The primary patents for naproxen have expired, leading to a competitive generic market. This has facilitated the entry of multiple manufacturers, including Indian exporters, into global markets. The absence of active patents allows for the production and export of generic naproxen without infringement concerns, promoting wider accessibility and affordability.

In June 2024, the EMA concluded a periodic safety update report single assessment (PSUSA/00002125/202308) for naproxen, resulting in a variation to the marketing authorization to enhance safety information. (ema.europa.eu)

In March 2023, the EMA completed a PSUSA (PSUSA/00001270/202204) for the combination of esomeprazole and naproxen, leading to amendments in product information to reflect updated safety data. (ema.europa.eu)

These developments underscore the importance of continuous pharmacovigilance and regulatory compliance for naproxen manufacturers and exporters.

India's pharmaceutical industry, including the production of Naproxen, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70% of APIs and KSMs used in Indian pharmaceutical manufacturing are sourced from China. This dependency exposes the supply chain to potential disruptions stemming from geopolitical tensions, trade policy changes, and environmental regulations in China.

For instance, in 2024, stringent environmental regulations in China led to the shutdown of numerous chemical factories, causing a significant increase in the prices of KSMs and subsequent APIs. This event underscored the vulnerability of India's pharmaceutical supply chain to external factors affecting Chinese manufacturing.

Our proprietary trade data indicates that the top five exporters of Naproxen from India account for 60.2% of the total export value, with MYLAN LABORATORIES LIMITED alone contributing 17.4%. This high supplier concentration poses a risk, as any operational or compliance issues within these key companies could disrupt the supply chain.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic manufacturing of APIs and reduce import dependence. As of November 2024, two greenfield plants were inaugurated under this scheme to produce critical pharmaceutical ingredients, marking a significant step towards supply chain diversification.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are susceptible to geopolitical tensions that can lead to delays and increased transportation costs. Additionally, ongoing US-China trade tensions have the potential to disrupt the supply of essential raw materials for pharmaceutical manufacturing.

Regulatory bodies such as the FDA and EMA have issued alerts regarding drug shortages resulting from these supply chain disruptions. For example, in July 2025, the FDA highlighted shortages of certain medications due to supply chain vulnerabilities, emphasizing the need for robust risk management strategies.

To enhance the resilience of the Naproxen supply chain, the following actions are recommended:

• Diversify API and KSM Sources: Develop alternative sourcing strategies to reduce reliance on Chinese imports, including partnerships with suppliers from other countries.

• Strengthen Domestic Manufacturing: Leverage government initiatives like the PLI scheme to invest in local production facilities for APIs and KSMs.

• Enhance Supplier Due Diligence: Conduct regular assessments of key suppliers to identify potential risks and develop contingency plans.

• Monitor Geopolitical Developments: Establish a monitoring system for geopolitical events that could impact shipping routes and raw material availability.

• Implement Supply Chain Transparency: Utilize technology to gain real-time visibility into the supply chain, enabling prompt responses to disruptions.

RISK_LEVEL: MEDIUM